Krsnaa Diagnostics Limited (KRSNAA) - Net Assets
Based on the latest financial reports, Krsnaa Diagnostics Limited (KRSNAA) has net assets worth Rs9.23 Billion INR (≈ $99.81 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs15.07 Billion ≈ $162.94 Million USD) and total liabilities (Rs5.84 Billion ≈ $63.13 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check KRSNAA strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs9.23 Billion |
| % of Total Assets | 61.26% |
| Annual Growth Rate | 35.94% |
| 5-Year Change | 280.73% |
| 10-Year Change | N/A |
| Growth Volatility | 101.21 |
Krsnaa Diagnostics Limited - Net Assets Trend (2017–2025)
This chart illustrates how Krsnaa Diagnostics Limited's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see KRSNAA market cap.
Annual Net Assets for Krsnaa Diagnostics Limited (2017–2025)
The table below shows the annual net assets of Krsnaa Diagnostics Limited from 2017 to 2025. Also explore Krsnaa Diagnostics Limited (KRSNAA) net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | Rs8.83 Billion ≈ $95.47 Million |
+9.01% |
| 2024-03-31 | Rs8.10 Billion ≈ $87.58 Million |
+9.62% |
| 2023-03-31 | Rs7.39 Billion ≈ $79.89 Million |
+10.47% |
| 2022-03-31 | Rs6.69 Billion ≈ $72.32 Million |
+188.40% |
| 2021-03-31 | Rs2.32 Billion ≈ $25.08 Million |
+217.71% |
| 2020-03-31 | Rs-1.97 Billion ≈ $-21.30 Million |
-131.95% |
| 2019-03-31 | Rs-849.21 Million ≈ $-9.18 Million |
-270.90% |
| 2018-03-31 | Rs-228.96 Million ≈ $-2.48 Million |
-130.24% |
| 2017-03-31 | Rs757.06 Million ≈ $8.19 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Krsnaa Diagnostics Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 207902652500.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rs2.00 Billion | 22.71% |
| Common Stock | Rs161.45 Million | 1.83% |
| Other Comprehensive Income | Rs64.38 Million | 0.73% |
| Other Components | Rs6.60 Billion | 74.73% |
| Total Equity | Rs8.83 Billion | 100.00% |
Krsnaa Diagnostics Limited Competitors by Market Cap
The table below lists competitors of Krsnaa Diagnostics Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Anika Therapeutics Inc
NASDAQ:ANIK
|
$196.52 Million |
|
Indeks Bilgisayar Sistemleri Muhendislik Sanayi ve Ticaret AS
IS:INDES
|
$196.54 Million |
|
Exicon Co. Ltd
KQ:092870
|
$196.56 Million |
|
Sentral REIT
KLSE:5123
|
$196.60 Million |
|
Nampak
JSE:NPK
|
$196.45 Million |
|
Legal & General Group PLC
LSE:LGEN
|
$196.39 Million |
|
Toro Ltd
NASDAQ:TORO
|
$196.30 Million |
|
Taigen Biopharmaceuticals Holdings Ltd
TWO:4157
|
$196.23 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Krsnaa Diagnostics Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 8,098,020,000 to 8,827,700,000, a change of 729,680,000 (9.0%).
- Net income of 776,080,000 contributed positively to equity growth.
- Dividend payments of 80,720,000 reduced retained earnings.
- Other comprehensive income increased equity by 32,950,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs776.08 Million | +8.79% |
| Dividends Paid | Rs80.72 Million | -0.91% |
| Other Comprehensive Income | Rs32.95 Million | +0.37% |
| Other Changes | Rs1.37 Million | +0.02% |
| Total Change | Rs- | 9.01% |
Book Value vs Market Value Analysis
This analysis compares Krsnaa Diagnostics Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.09x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 7.64x to 2.09x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-03-31 | Rs73.33 | Rs560.00 | x |
| 2018-03-31 | Rs-22.18 | Rs560.00 | x |
| 2019-03-31 | Rs-27.05 | Rs560.00 | x |
| 2020-03-31 | Rs-62.74 | Rs560.00 | x |
| 2021-03-31 | Rs73.85 | Rs560.00 | x |
| 2022-03-31 | Rs229.02 | Rs560.00 | x |
| 2023-03-31 | Rs229.44 | Rs560.00 | x |
| 2024-03-31 | Rs246.60 | Rs560.00 | x |
| 2025-03-31 | Rs267.99 | Rs560.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Krsnaa Diagnostics Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.79%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.82%
- • Asset Turnover: 0.56x
- • Equity Multiplier: 1.45x
- Recent ROE (8.79%) is below the historical average (12.09%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -5.18% | -6.90% | 0.32x | 2.32x | Rs-114.95 Million |
| 2018 | 0.00% | -55.92% | 0.37x | 0.00x | Rs-578.67 Million |
| 2019 | 0.00% | -27.75% | 0.40x | 0.00x | Rs-495.65 Million |
| 2020 | 0.00% | -43.32% | 0.41x | 0.00x | Rs-922.53 Million |
| 2021 | 79.76% | 46.65% | 0.66x | 2.61x | Rs1.62 Billion |
| 2022 | 9.99% | 15.02% | 0.52x | 1.28x | Rs-529.00K |
| 2023 | 8.41% | 12.75% | 0.54x | 1.23x | Rs-117.63 Million |
| 2024 | 7.02% | 9.17% | 0.53x | 1.45x | Rs-241.43 Million |
| 2025 | 8.79% | 10.82% | 0.56x | 1.45x | Rs-106.69 Million |
Industry Comparison
This section compares Krsnaa Diagnostics Limited's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $6,676,028,424
- Average return on equity (ROE) among peers: 16.64%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Krsnaa Diagnostics Limited (KRSNAA) | Rs9.23 Billion | -5.18% | 0.63x | $196.45 Million |
| Dr. Lal Path Labs Ltd. (LALPATHLAB) | $18.85 Billion | 18.97% | 0.30x | $3.39 Billion |
| Metropolis Healthcare Limited (METROPOLIS) | $9.91 Billion | 14.42% | 0.52x | $329.99 Million |
| Syngene International Limited (SYNGENE) | $2.21 Billion | 12.32% | 1.28x | $1.72 Billion |
| Thyrocare Technologies Limited (THYROCARE) | $4.27 Billion | 26.48% | 0.28x | $991.71 Million |
| Vijaya Diagnostic Centre Limited (VIJAYA) | $3.59 Billion | 23.52% | 0.51x | $1.66 Billion |
| Vimta Labs Limited (VIMTALABS) | $1.22 Billion | 4.14% | 0.20x | $307.19 Million |
About Krsnaa Diagnostics Limited
Krsnaa Diagnostics Limited provides diagnostic services in India. It offers a range radiology services, including computed tomography scans, magnetic resonance imaging, X-rays, and ultrasound and advanced imaging; pathology services, such as laboratory, and home collection and preventive health; and teleradiology and telepathology services. The company also provides other diagnostics services, su… Read more